A detailed history of Samlyn Capital, LLC transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Samlyn Capital, LLC holds 6,123,021 shares of CRVS stock, worth $55.5 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
6,123,021
Previous 2,348,363 160.74%
Holding current value
$55.5 Million
Previous $4.18 Million 166.58%
% of portfolio
0.2%
Previous 0.07%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.36 - $2.29 $5.13 Million - $8.64 Million
3,774,658 Added 160.74%
6,123,021 $11.1 Million
Q1 2024

May 15, 2024

SELL
$1.76 - $2.41 $260,296 - $356,429
-147,896 Reduced 5.92%
2,348,363 $4.18 Million
Q4 2023

Feb 14, 2024

BUY
$1.08 - $1.92 $97,734 - $173,750
90,495 Added 3.76%
2,496,259 $4.39 Million
Q3 2023

Nov 14, 2023

BUY
$1.41 - $2.97 $422,765 - $890,506
299,834 Added 14.24%
2,405,764 $3.51 Million
Q2 2023

Aug 14, 2023

BUY
$1.0 - $3.86 $2.11 Million - $8.13 Million
2,105,930 New
2,105,930 $4.82 Million

Others Institutions Holding CRVS

About Corvus Pharmaceuticals, Inc.


  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $422M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track This Portfolio

Track Samlyn Capital, LLC Portfolio

Follow Samlyn Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Samlyn Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Samlyn Capital, LLC with notifications on news.